It’s finally over: Biogen, Eisai scrap big Alzheimer’s PhIIIs after a predictable BACE catastrophe raises safety fears
Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.
We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.